Tag:
hostile takeover
Latest Headlines
Latest Headlines
HGS puts 'poison pill' in its arsenal against GSK
Human Genome Sciences has added a poison pill to its portfolio as it tries to fend off the hostile takeover by its longtime partner GlaxoSmithKline.
Glaxo goes hostile on HGS with $2.6B bid
Prepare yourself for a drawn-out buyout battle--and lots of debate about the lupus treatment Benlysta.
Roche's $5.7B Illumina bid risks standing alone
In the wake of Roche's ( $RHHBY ) $5.7 billion hostile takeover bid for gene sequencing company Illumina ( $ILMN ), the jury is still out as to what it means for the industry at large. On the one hand,
Valeant offers a stick, a carrot and a May 12 deadline to Cephalon investors
The CEO of Canada's Valeant Pharmaceuticals has marshaled all of his arguments in favor of a hostile takeover of Cephalon ( $CEPH ) in a letter designed to woo shareholders, offering to bump the pharma
Valeant may sweeten Cephalon bid
Valeant says it just might be willing to up its bid for Cephalon--once it gets its hands on the books for its due diligence work. Cephalon has been fending off Valeant's hostile acquisition effort,
Bankers expect more Japanese-led M&A
Yesterday, we heard that analysts are expecting more hostile bids to heat up pharma M&A. However, experts now are predicting that Japanese drugmakers will become bigger players in pharma
Analysts: Expect more hostile bids in pharma
To some analysts, Valeant Pharmaceuticals' offer for Cephalon makes it official: The pharma industry is living in a new era of hostile acquisitions. On the heels of Sanofi-Aventis' hostile bid for
Fund sues Cephalon as Valeant hints at higher bid
Valeant Pharmaceuticals ( $VRX ) may get some help in buying Cephalon ( $CEPH ) from one of that company's investors. A Pennsylvania pension fund has sued Cephalon, saying management has simply refused
Cephalon shares rocket up after Valeant makes $5.7B hostile bid
Rebuffed after making a private overture, Canada's Valeant Pharmaceuticals ( $VRX ) has gone hostile in its pursuit of Cephalon, offering $5.7 billion for the business and threatening to walk in a
Sanofi raises big loan as it plots Genzyme buyout strategy
Sanofi-Aventis may not be able to get the time of day from Genzyme's board, but the pharma giant says its hostile takeover attempt faces no antitrust concerns in the U.S. Sanofi says that regulators
